Vanda Pharmaceuticals | VNDA - Operating Expenses


Vanda Pharmaceuticals reported $-1.14B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.78B 242M Mar/2026
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Veracyte USD 119.99M 3.99M Mar/2026